scholarly journals Performance of Verigene Rapid Diagnostic Testing for Detection of Inpatient Pediatric Bacteremia

2021 ◽  
Vol 26 (5) ◽  
pp. 472-477
Author(s):  
Amy Kruger Howard ◽  
Kimberly Claeys ◽  
Jessica M. Biggs ◽  
Kristine A. Parbuoni ◽  
Kristie Johnson ◽  
...  
Keyword(s):  
Diagnostic Testing ◽  
Decision Support Tool ◽  
Clinical Decision ◽  
Gram Stain ◽  
Support Tool ◽  
Rapid Diagnostic Testing ◽  
Children's Hospital ◽  
Percent Agreement ◽  
Children’S Hospital ◽  
Resistance Markers

OBJECTIVE Verigene blood culture panels comprise rapid diagnostic testing, which aids in early bacteremia species identification. This study determined the concordance of Verigene rapid diagnostic results compared with the Vitek reference standard in patients admitted to a children's hospital. METHODS This was a 3-year retrospective observational study of neonatal and pediatric patients ≤18 years admitted to a children's hospital with confirmed bacteremia for whom Verigene testing was performed. Verigene testing was conducted on cultures with reported growth on Gram stain and final organism speciation confirmed via Vitek. Percent concordance and positive percent agreement with 95% CIs were calculated for Verigene panel-identifiable organisms. Negative percent agreement with 95% CIs was calculated for non-panel organisms. Time-to-result was calculated from Gram stain reporting to both Verigene and Vitek final organism susceptibility. RESULTS One hundred thirty-five Gram-positive (GP) and 51 Gram-negative (GN) isolates were identified through Vitek. Verigene GP panel-detectable organisms were correctly identified 96.9% (125/129) at the genus level and 95.3% (123/129) at the species level. Overall positive percent agreement was 95.3 (CI: 90.2–98.3). Negative percent agreement was 83.3 (CI: 35.9–99.6) for the 6 non-panel GP organisms. All GN isolates were correctly identified on Verigene. Median time-to-result was 2.9 hours (IQR 2.6, 3.2) and 44.4 hours (IQR: 35.4, 52.5) for Verigene and final susceptibilities, respectively. There was a statistically significant time savings of 41.5 hours (CI: 29.8–53.2) for identification and detection of resistance markers (p < 0.0001). CONCLUSION Verigene concordance at our institution aligns with results from previously published studies and can be considered a reliable clinical decision-support tool.

scholarly journals Clinical Impact of Malaria Rapid Diagnostic Testing at a US Children’s Hospital

2019 ◽  
Vol 9 (3) ◽  
pp. 298-304
Author(s):  
Leslie A Enane ◽  
Kaede V Sullivan ◽  
Evangelos Spyridakis ◽  
Kristen A Feemster
Keyword(s):  
Diagnostic Testing ◽  
Clinical Signs ◽  
Length Of Hospital Stay ◽  
Clinical Impact ◽  
Rapid Diagnostic Testing ◽  
Children's Hospital ◽  
Antimalarial Therapy ◽  
Children’S Hospital ◽  
The Mean ◽  
Mean Time

Abstract Background Children who develop malaria after returning to a setting in which the disease is not endemic are at high risk for critical delays in diagnosis and initiation of antimalarial therapy. We assessed the clinical impact of the implementation of malaria rapid diagnostic testing (RDT) on the management of children with malaria at an urban US children’s hospital that serves a large immigrant population. Methods This was a retrospective cohort study of all children diagnosed with laboratory-confirmed malaria at the Children’s Hospital of Philadelphia (CHOP) between 2000 and 2014. RDT using a US Food and Drug Administration–approved immunochromatographic assay was introduced at CHOP on August 1, 2007. We compared clinical management and outcomes of patients with malaria diagnosed before and after RDT introduction. Results We analyzed 82 pediatric malaria cases (32 before and 50 after RDT implementation). The majority of these patients had traveled to West Africa (91.5%) and were infected with Plasmodium falciparum (80.5%). The mean time to a positive result decreased from 10.4 to 0.9 hours (P < .001) after the introduction of RDT for patients with P falciparum. The mean time to antimalarial therapy decreased from 13.1 to 6.9 hours (P =; .023) in hospitalized patients. We found no significant reduction in the mean number of clinical signs of severe malaria between 0 and 48 hours of hospitalization and no difference in the need for exchange transfusion, time to resolution of parasitemia, or length of hospital stay. Conclusions Implementation of RDT for malaria was associated with shorter times to malaria diagnosis and initiation of antimalarial therapy. The results of this study support RDT in the optimal management of patients with malaria who present in settings in which the disease is not endemic.

scholarly journals Challenges involved in establishing a web-based clinical decision support tool in community health centers

Healthcare ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 100488
Author(s):  
Rachel Gold ◽  
Mary Middendorf ◽  
John Heintzman ◽  
Joan Nelson ◽  
Patrick O'Connor ◽  
...  
Keyword(s):  
Decision Support ◽  
Community Health ◽  
Clinical Decision Support ◽  
Community Health Centers ◽  
Decision Support Tool ◽  
Clinical Decision ◽  
Health Centers ◽  
Web Based ◽  
Support Tool ◽  
Clinical Decision Support Tool

scholarly journals Best Paper Selection

2018 ◽  
Vol 27 (01) ◽  
pp. 127-128
Keyword(s):  
Decision Support ◽  
Postoperative Delirium ◽  
Decision Support Tool ◽  
Clinical Decision ◽  
Knowledge Bases ◽  
Free Text ◽  
Health Records ◽  
Support Tool ◽  
Team Selection ◽  
Order Sets

Chen JH, Alagappan M, Goldstein MK, Asch SM, Altman RB. Decaying relevance of clinical data towards future decisions in data-driven inpatient clinical order sets. Int J Med Inform 2017 Jun;102:71-9 https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/28495350/ Ebadi A, Tighe PJ, Zhang L, Rashidi P. DisTeam: A decision support tool for surgical team selection. Artif Intell Med 2017 Feb;76:16-26 https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/28363285/ Fung KW, Kapusnik-Uner J, Cunningham J, Higby-Baker S, Bodenreider O. Comparison of three commercial knowledge bases for detection of drug-drug interactions in clinical decision support. J Am Med Inform Assoc 2017 Jul 1;24(4):806-12 https://academic.oup.com/jamia/article-lookup/doi/10.1093/jamia/ocx010 Mikalsen KØ, Soguero-Ruiz C, Jensen K, Hindberg K, Gran M, Revhaug A, Lindsetmo RO, Skrøvseth SO, Godtliebsen F, Jenssen R. Using anchors from free text in electronic health records to diagnose postoperative delirium. Comput Methods Programs Biomed 2017 Dec;152:105-14 https://linkinghub.elsevier.com/retrieve/pii/S0169-2607(17)31154-9

scholarly journals Reduced Length of Stay Using Clinical Decision Support Tool (ASAP) for Empiric Antibiotic Selection

2020 ◽  
Vol 41 (S1) ◽  
pp. s368-s368
Author(s):  
Mary Acree ◽  
Kamaljit Singh ◽  
Urmila Ravichandran ◽  
Jennifer Grant ◽  
Gary Fleming ◽  
...  
Keyword(s):  
Decision Support ◽  
Length Of Stay ◽  
Electronic Health Record ◽  
Clinical Decision Support ◽  
Decision Support Tool ◽  
Clinical Decision ◽  
Health Record ◽  
Antibiotic Selection ◽  
Support Tool ◽  
Empiric Antibiotic

Background: Empiric antibiotic selection is challenging and requires knowledge of the local antibiogram, national guidelines and patient-specific factors, such as drug allergy and recent antibiotic exposure. Clinical decision support for empiric antibiotic selection has the potential to improve adherence to guidelines and improve patient outcomes. Methods: At NorthShore University HealthSystem, a 4-hospital, 789 bed system, an automated point-of-care decision support tool referred to as Antimicrobial Stewardship Assistance Program (ASAP) was created for empiric antibiotic selection for 4 infectious syndromes: pneumonia, skin and soft-tissue infections, urinary tract infection, and intra-abdominal infection. The tool input data from the electronic health record, which can be modified by any user. Using an algorithm created with electronic health record data, antibiogram data, and national guidelines, the tool produces an antibiotic recommendation that can be ordered via a link to order entry. If the tool identifies a patient with a high likelihood for a multidrug-resistant infection, a consultation by an infectious diseases specialist is recommended. Utilization of the tool and associated outcomes were evaluated from July 2018 to May 2019. Results: The ASAP tool was executed by 140 unique, noninfectious diseases providers 790 times. The tool was utilized most often for pneumonia (194 tool uses), followed by urinary tract infection (166 tool uses). The most common provider type to use the tool was an internal medicine hospitalist. The tool increased adherence to the recommended antibiotic regimen for each condition. Antibiotic appropriateness was assessed by an infectious diseases physician. Antibiotics were considered appropriate when they were similar to the antibiotic regimen recommended by the ASAP. Inappropriate antibiotics were classified as broad or narrow. When antibiotic coverage was appropriate, hospital length of stay was statistically significantly shorter (4.8 days vs 6.8 days for broad antibiotics vs 7.4 days for narrow antibiotics; P < .01). No significant differences were identified in mortality or readmission. Conclusions: A clinical decision support tool in the electronic health record can improve adherence to recommended empiric antibiotic therapy. Use of appropriate antibiotics recommended by such a tool can reduce hospital length of stay.Funding: NoneDisclosures: None

scholarly journals The use of a clinical decision support tool to assess the risk of QT drug–drug interactions in community pharmacies

2021 ◽  
Vol 12 ◽  
pp. 204209862199609
Author(s):  
Florine A. Berger ◽  
Heleen van der Sijs ◽  
Teun van Gelder ◽  
Patricia M. L. A. van den Bemt
Keyword(s):  
Decision Support ◽  
Drug Interactions ◽  
Clinical Decision Support ◽  
Decision Support Tool ◽  
Clinical Decision ◽  
Community Pharmacies ◽  
Support Tool ◽  
Interacting Agents ◽  
Before And After ◽  
Structured Approach

Introduction: The handling of drug–drug interactions regarding QTc-prolongation (QT-DDIs) is not well defined. A clinical decision support (CDS) tool will support risk management of QT-DDIs. Therefore, we studied the effect of a CDS tool on the proportion of QT-DDIs for which an intervention was considered by pharmacists. Methods: An intervention study was performed using a pre- and post-design in 20 community pharmacies in The Netherlands. All QT-DDIs that occurred during a before- and after-period of three months were included. The impact of the use of a CDS tool to support the handling of QT-DDIs was studied. For each QT-DDI, handling of the QT-DDI and patient characteristics were extracted from the pharmacy information system. Primary outcome was the proportion of QT-DDIs with an intervention. Secondary outcomes were the type of interventions and the time associated with handling QT-DDIs. Logistic regression analysis was used to analyse the primary outcome. Results: Two hundred and forty-four QT-DDIs pre-CDS tool and 157 QT-DDIs post-CDS tool were included. Pharmacists intervened in 43.0% and 35.7% of the QT-DDIs pre- and post-CDS tool respectively (odds ratio 0.74; 95% confidence interval 0.49–1.11). Substitution of interacting agents was the most frequent intervention. Pharmacists spent 20.8 ± 3.5 min (mean ± SD) on handling QT-DDIs pre-CDS tool, which was reduced to 14.9 ± 2.4 min (mean ± SD) post-CDS tool. Of these, 4.5 ± 0.7 min (mean ± SD) were spent on the CDS tool. Conclusion: The CDS tool might be a first step to developing a tool to manage QT-DDIs via a structured approach. Improvement of the tool is needed in order to increase its diagnostic value and reduce redundant QT-DDI alerts. Plain Language Summary The use of a tool to support the handling of QTc-prolonging drug interactions in community pharmacies Introduction: Several drugs have the ability to cause heart rhythm disturbances as a rare side effect. This rhythm disturbance is called QTc-interval prolongation. It may result in cardiac arrest. For health care professionals, such as physicians and pharmacists, it is difficult to decide whether or not it is safe to proceed treating a patient with combinations of two or more of these QT-prolonging drugs. Recently, a tool was developed that supports the risk management of these QT drug–drug interactions (QT-DDIs). Methods: In this study, we studied the effect of this tool on the proportion of QT-DDIs for which an intervention was considered by pharmacists. An intervention study was performed using a pre- and post-design in 20 community pharmacies in The Netherlands. All QT-DDIs that occurred during a before- and after-period of 3 months were included. Results: Two hundred and forty-four QT-DDIs pre-implementation of the tool and 157 QT-DDIs post-implementation of the tool were included. Pharmacists intervened in 43.0% of the QT-DDIs before the tool was implemented and in 35.7% after implementation of the tool. Substitution of one of the interacting agents was the most frequent intervention. Pharmacists spent less time on handling QT-DDIs when the tool was used. Conclusion: The clinical decision support tool might be a first step to developing a tool to manage QT-DDIs via a structured approach.

scholarly journals Duplicate Laboratory Test Reduction Using a Clinical Decision Support Tool

2014 ◽  
Vol 141 (5) ◽  
pp. 718-723 ◽  
Author(s):  
Gary W. Procop ◽  
Lisa M. Yerian ◽  
Robert Wyllie ◽  
A. Marc Harrison ◽  
Kandice Kottke-Marchant
Keyword(s):  
Decision Support ◽  
Laboratory Test ◽  
Clinical Decision Support ◽  
Decision Support Tool ◽  
Clinical Decision ◽  
Support Tool ◽  
Clinical Decision Support Tool

41 Enhancing Burn Medical Care During a Disaster Using a Novel Augmented-Reality Application

2021 ◽  
Vol 42 (Supplement_1) ◽  
pp. S31-S31
Author(s):  
Sena Veazey ◽  
Maria SerioMelvin ◽  
David E Luellen ◽  
Angela Samosorn ◽  
Alexandria Helms ◽  
...  
Keyword(s):  
Decision Support ◽  
Augmented Reality ◽  
Clinical Decision Support ◽  
Decision Support Tool ◽  
Clinical Decision ◽  
Burn Injuries ◽  
Medical Decision ◽  
Support Tool ◽  
Burn Care ◽  
Clinical Decision Support Tool

Abstract Introduction In disaster or mass casualty situations, access to remote burn care experts, communication, or resources may be limited. Furthermore, burn injuries are complex and require substantial training and knowledge beyond basic clinical care. Development and use of decision support (DS) technologies may provide a solution for addressing this need. Devices capable of delivering burn management recommendations can enhance the provider’s ability to make decisions and perform interventions in complex care settings. When coupled with merging augmented reality (AR) technologies these tools may provide additional capabilities to enhance medical decision-making, visualization, and workflow when managing burns. For this project, we developed a novel AR-based application with enhanced integrated clinical practice guidelines (CPGs) to manage large burn injuries for use in different environments, such as disasters. Methods We identified an AR system that met our requirements to include portability, infrared camera, gesture and voice control, hands-free control, head-mounted display, and customized application development abilities. Our goal was to adapt burn CPGs to make use of AR concepts as part of an AR-enabled burn clinical decision support system supporting four sub-applications to assist users with specific interventional tasks relevant to burn care. We integrated relevant CPGs and a media library with photos and videos as additional references. Results We successfully developed a clinical decision support tool that integrates burn CPGs with enhanced capabilities utilizing AR technology. The main interface allows input of patient demographics and injuries with step-by-step guidelines that follow typical burn management care and workflow. There are four sub-applications to assist with these tasks, which include: 1) semi-automated burn wound mapping to calculate total body surface area; 2) hourly burn fluid titration and recommendations for resuscitation; 3) medication calculator for accurate dosing in preparation for procedures and 4) escharotomy instructor with holographic overlays. Conclusions We developed a novel AR-based clinical decision support tool for management of burn injuries. Development included adaptation of CPGs into a format to guide the user through burn management using AR concepts. The application will be tested in a prospective research study to determine the effectiveness, timeliness, and performance of subjects using this AR-software compared to standard of care. We fully expect that the tool will reduce cognitive workload and errors, ensuring safety and proper adherence to guidelines.

Sign in / Sign up

Export Citation Format

Share Document